LUMICKS Technologies B.V.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
LUMICKS Technologies B.V. - overview
Established
2014
Location
Amsterdam, -, Netherlands
Primary Industry
Biotechnology
About
LUMICKS Technologies, based in the Netherlands, specializes in advanced technologies for biomolecular and cellular research, delivering innovative solutions that enhance understanding of molecular interactions and therapeutic mechanisms. Founded in 2014, LUMICKS Technologies B. V. is focused on providing scientific instruments for academic and pharmaceutical research.
The company has conducted a total of 3 deals, with its most recent funding round, Series D, taking place on October 11, 2024, raising EUR 77. 60 mn from investors including Farallon Capital Management and T. Rowe Price. The CEO is Olivier Heyning and the founder is Erwin Peterman.
LUMICKS offers advanced technologies primarily designed for academic and pharmaceutical research, focusing on biomolecular mechanisms and cellular interactions. Their core products include Cell Avidity, which quantifies binding strength between cells and proteins, and Dynamic Single-Molecule solutions for real-time observation of molecular interactions. These products serve a global clientele, including universities and pharmaceutical companies, with significant demand in North America, Europe, and parts of Asia. In the most recent fiscal year of 2022, LUMICKS reported revenue of EUR 18,878,807.
20 and an EBITDA of EUR -32,684,626. 60. The company's revenue is generated through sales of research instruments and services, primarily under a B2B model with academic institutions and pharmaceutical firms. In October 2024, LUMICKS Technologies B.
V. secured EUR 20 million in venture debt from the European Investment Bank. This funding will expedite the development and launch of their advanced cell avidity platform aimed at cancer immunotherapy research. The company plans to expand its offerings and may target new markets in North America and Asia by 2025, enhancing their product portfolio to better serve the growing needs in these regions.
Current Investors
Gilde Healthcare, T Rowe Price, Pura Vida Investments
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Medical Equipment Distributors, Medical Software
Website
www.lumicks.com
Company Stage
Series D
Total Amount Raised
Subscriber access only
LUMICKS Technologies B.V. - timeline of key events
LUMICKS Technologies B.V. - financials
| Fiscal Year Ended | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Mar 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 11,685,000 | 14,960,000 | 17,915,000 | - | - | - |
| % Revenue Growth (YoY) | - | 28.0% | 19.8% | - | - | - |
| EBITDA (USD) | (2,249,000) | (22,199,000) | (31,016,000) | - | - | - |
| Operating Income (USD) | (3,721,000) | (24,999,000) | (34,900,000) | - | - | - |
| Operating Margin | (31.8%) | (167.1%) | (194.8%) | - | - | - |
| % EBITDA Margin | (19.2%) | (148.4%) | (173.1%) | - | - | - |
| NET Income (USD) | (4,177,000) | (22,283,000) | (34,104,000) | - | - | - |
| % Net Margin | (35.7%) | (149.0%) | (190.4%) | - | - | - |
LUMICKS Technologies B.V. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.